Dronedarone for atrial fibrillation: a new therapeutic agent.

Article Details

Citation
Copy to clipboard

Patel PD, Bhuriya R, Patel DD, Arora BL, Singh PP, Arora RR

Dronedarone for atrial fibrillation: a new therapeutic agent.

Vasc Health Risk Manag. 2009;5:635-42. doi: 10.2147/vhrm.s6185. Epub 2009 Aug 6.

PubMed ID
19688104 [ View in PubMed
]
Abstract

Atrial fibrillation is the most common of the serious cardiac rhythm disturbances and is responsible for substantial morbidity and mortality. Amiodarone is currently one of the most widely used and most effective antiarrhythmic agents for atrial fibrillation. But during chronic usage amiodarone can cause some serious extra cardiac adverse effects, including effects on the thyroid. Dronedarone is a newer therapeutic agent with a structural resemblance to amiodarone, with two molecular changes, and with a better side effect profile. Dronedarone is a multichannel blocker and, like amiodarone, possesses both a rhythm and a rate control property in atrial fibrillation. The US Food and Drug Administration approved dronedarone for atrial fibrillation on July 2, 2009. In this review, we discuss the role of dronedarone in atrial fibrillation.

DrugBank Data that Cites this Article

Drugs